Amoéba Valuation
Is A1H undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A1H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A1H's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A1H's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A1H?
Key metric: As A1H is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A1H's PB Ratio? | |
|---|---|
| PB Ratio | -5.4x |
| Book | -€7.05m |
| Market Cap | €38.21m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -9.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A1H's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
BNN BRAIN Biotech | 4.2x | 71.5% | €68.8m |
NTG Nabaltec | 0.8x | 4.3% | €123.6m |
2HRA H&R GmbH KGaA | 0.3x | 52.9% | €127.3m |
BIG1 Bio-Gate | 2.7x | n/a | €6.3m |
A1H Amoéba | n/a | 44.8% | €38.2m |
Price-To-Book vs Peers: A1H has negative equity and a Price-To-Book Ratio (-5.4x) compared to the peer average (2x).
Price to Book Ratio vs Industry
How does A1H's PB Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Book vs Industry: A1H has negative equity and a Price-To-Book Ratio (-5.4x) compared to the European Chemicals industry average (1.4x).
Price to Book Ratio vs Fair Ratio
What is A1H's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -5.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A1H's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
UBE
JP¥237.9b
Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.
UBE
JP¥15.00
7D
6.4%
1Y
5.6%
Ecora Resources
UK£162.5m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
HGR
UK£0.76
7D
-1.4%
1Y
-29.4%
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.91
7D
2.1%
1Y
-15.5%